ArticleDermatology and therapy2025
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of OBI-858 for the Treatment of Moderate-to-Severe Glabellar Lines.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOBI-858 is a novel 760 kDa botulinum toxin type A complex produced by Clostridium botulinum, and currently under development for esthetic applications. This phase II clinical trial aimed to evaluate the efficacy, safety, and optimal dose of OBI-858 for treating moderate-to-severe glabellar lines.
methodsIn this multicenter, randomized, double-blind, placebo-controlled study, subjects received a single dose of OBI-858 (10U or 20U) or placebo for the treatment of glabellar lines. Subjects were followed for 24-week with efficacy assessed by Facial Wrinkle Scale (FWS), which grades dynamic glabellar line severity (GLS) and Global Aesthetic Improvement Scale (GAIS), along with subject-reported satisfaction. Safety assessments included treatment-emergent adverse events (AEs) and immunogenicity testing.
resultsAt week 4, 74.42% of subjects in the 20U group and 58.70% in the 10U group achieved ≥ 2-point improvement in Glabellar Line as assessed by both investigators and subjects, compared with 0% in the placebo group (p < 0.001). In the 24-week analysis, both 10U and 20U groups demonstrated a rapid onset of GLS 0 or 1 responder rates by day 3, achieving peak rates by week 2. From week 4 to week 20, the 20U group consistently exhibited superior efficacy, showing higher responder rates. Overall, both groups maintained sustained efficacy through week 24. Furthermore, GAIS and subjects reporting satisfaction scores peaked at week 2 and remained favorable in the 20U group through week 24, with nearly 60% of subjects reporting satisfaction at the study's end. OBI-858 was well tolerated, with no treatment-related serious AE or new antidrug antibody (ADA) development observed during the study.
conclusionsOBI-858 demonstrated a favorable safety profile, with no new ADA development observed during the study, along with dose-dependent efficacy and subject satisfaction in treating glabellar lines.
trial registrationTaiwanClinicalTrials.tw: 1139014205.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.